These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

4340 related items for PubMed ID: 4552317

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Hexamethylmelamine (NSC-13875) alone and in combination with 5-(3, 3-dimethyl-1-triazeno) imidazole-4-carboxamide (NSC-45388) in the treatment of advanced cancer.
    Stolinsky DC, Bogdon DL, Solomon J, Bateman JR.
    Cancer; 1972 Sep; 30(3):654-9. PubMed ID: 5075351
    [No Abstract] [Full Text] [Related]

  • 5. Intra-arterial infusion therapy with 5-(3,3-dimethyl-1-triazeno) imidazole-4-carboxamide (NSC 45388) for malignant melanoma.
    Einhorn LH, McBride CM, Luce JK, Caoili E, Gottlieb JA.
    Cancer; 1973 Oct; 32(4):749-55. PubMed ID: 4751911
    [No Abstract] [Full Text] [Related]

  • 6. Clinical experience with 5-(3,3-bis(2-chloroethyl)-1-triazeno)imidazole-4-carboxamide (NSC-82196) in the treatment of metastatic malignant melanoma.
    Falkson G, Van der Merwe AM, Falkson HC.
    Cancer Chemother Rep; 1972 Oct; 56(5):671-7. PubMed ID: 4569061
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide (NSC-45388) in the treatment of malignant tumors other than melanoma.
    Kingra GS, Comis R, Olson KB, Horton J.
    Cancer Chemother Rep; 1971 Jun; 55(3):281-3. PubMed ID: 5115849
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Effective treatment of Kaposi's sarcoma with 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide (NSC-45388).
    Vogel CL, Primack A, Owor R, Kyalwazi SK.
    Cancer Chemother Rep; 1973 Feb; 57(1):65-71. PubMed ID: 4704105
    [No Abstract] [Full Text] [Related]

  • 17. 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide (NSC-45388) in the treatment of lymphoma.
    Frei E, Luce JK, Talley RW, Vaitkevicius VK, Wilson HE.
    Cancer Chemother Rep; 1972 Oct; 56(5):667-70. PubMed ID: 4569060
    [No Abstract] [Full Text] [Related]

  • 18. Characteristics of prognosis and response to an imidazole carboxamide in malignant melanoma.
    Nathanson L, Wolter J, Horton J, Colsky J, Shnider BI, Schilling A.
    Clin Pharmacol Ther; 1971 Oct; 12(6):955-62. PubMed ID: 5134998
    [No Abstract] [Full Text] [Related]

  • 19. Evaluation of 4-carbethoxy-5(3,3-dimethyl-1-triazeno)-2-phenylimidazole (NSC-166721) and 4-carbethoxy-5-(3,3-dimethyl-1-triazeno)-2-methylimidazole (NSC-166722) as potential antitumor agents.
    Heyes J, Catherall EJ, Cockburn A.
    Cancer Chemother Rep; 1973 Oct; 57(3):263-8. PubMed ID: 4751253
    [No Abstract] [Full Text] [Related]

  • 20. Dacarbazine for malignant melanoma.
    Med Lett Drugs Ther; 1974 Mar 15; 16(6):27-8. PubMed ID: 4817357
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 217.